Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.

about

National assessment of early hospitalization after liver transplantation: Risk factors and association with patient survival.

P2860

Q38688657-DF0E991D-A2DF-4503-A593-D9D06FC849F7

P2860

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.

Item

http://www.wikidata.org/entity/Q40438926

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Simeprevir, daclatasvir and so ...... h decompensated liver disease.

@en

type

Item

label

Simeprevir, daclatasvir and so ...... h decompensated liver disease.

@en

prefLabel

Simeprevir, daclatasvir and so ...... h decompensated liver disease.

@en

P1476

Simeprevir, daclatasvir and so ...... h decompensated liver disease.

@en

P2093

A Vandevoorde

http://www.w3.org/2001/XMLSchema#string

B Jacquemyn

http://www.w3.org/2001/XMLSchema#string

D Luo

http://www.w3.org/2001/XMLSchema#string

E Lawitz

http://www.w3.org/2001/XMLSchema#string

F Poordad

http://www.w3.org/2001/XMLSchema#string

G Beets

http://www.w3.org/2001/XMLSchema#string

G Picchio

http://www.w3.org/2001/XMLSchema#string

J A Gutierrez

http://www.w3.org/2001/XMLSchema#string

L Vijgen

http://www.w3.org/2001/XMLSchema#string

M Beumont

http://www.w3.org/2001/XMLSchema#string

P2860

Natural history of hepatitis C

Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

Clinical outcomes of compensated and decompensated cirrhosis: A long term study.

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.

Treatment of hepatitis C in difficult-to-treat patients.

New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease.

P304

287-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JVH.12645

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27878906

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.

about

P2860

P2860

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921